Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CP What you have pointed out are factual pronouncements but time is the disdainer for the long, long investors here.
Some positive news for the future. But in the meantime there is the RS approaching sorry to say. I wish it weren't so for the long term investors on this board. There is a subset group (biomarker) identified where BAVI can produce Stat Sig OS results in NSCLC. Will see where this goes from here.
Pr announcements are in the wake.
Shorty on sideline more accumulation and upward price movement
Watch first & second Quarters of 2017 for possible NDA
Let's hope for the best. Thanks for informative information.
This would be a potentially significant development if most of the patients outside of the control arm exhibited the statistical significant improvements in OS months after the trail stoppage. Not that the statement below is alluding to this though it will be interesting to see how many patients fall into this category.
I think we all agree that the FDA, the Industry and everybody else involved wants to measure the performance of the drug and not of any treatment given after progression. So it might be that the sub-group about which CEO King is talking are the patients that had a 3rd ln treatment. Purely in terms of math theory one could say that if you exclude these that technically speaking the remaining patients are kind of a sub-group.
If your prediction holds the key will be how many patients would potentially fall into this category in the affected population at large.
You can always find some subgroup that performs better in post-hoc data mining. The marker will still have to be tested in a new trial. AS for how narrow, I predicted 25 patients or less with the biomarker
I would be delighted if this Biomarker is identified to be more expansive then in a certain subset group or groups. Parsing words in PR'S can draw many potential conclusions.
The SUNRISE stoppage in first interim analysis by DMC opened the data for analysis. Built into the trial where threshold analytical points by which subset groups could be determined with statistical significance in this case OS. This subset group could be broad based or narrow in focus will see when more information is revealed. There could and probably will be more subset groups identified. The outcome of a Phase 3 trail stoppage is seldom ever fully determined until post analysis.
Subset groups identified with statistical significance is very positive and can lead to many treatment regimens in several indications. BIO markers grouped together will be the path moving forward for treatments.
Why the issue with subsets in light of a phase 3 stoppage?
Not a LONG,LONG poster here but an investor in many BIOS over the years with some knowledge to bear.
What we have...
Bio marker established for subset. Potentially more subset bio markers can be ferreted out after further analysis of Sunrise. Combination therapy with subsets can potentially develop in many other indications. This is the key.
The Science is moving forward albeit not in block buster fashion
but through historical norms. The value is beginning to resonate with BP.
IMO.
Shorty owns the volume
I see the short term play. Any Nasdaq compliance in the cards in your opinion?
PP has joined the ever increasing field of BIOS establishing a Stat Sig bio marker for a subgroup of patients for combo therapy...... possibly at some point.
Perhaps IP value is gaining traction. Would be nice.
Heavy short activity for now.
Heavy shorting of stock a result of no results measurable enough to generate a scintilla of a profit. Quite the contrary heavy loses. Perhaps in a couple years with Avid? Unless of coarse the science garners a monetary partnership offer at some point?
Shorting has its validity to punish poor management.
Bio stocks should be placed in a different category
by SEC with a LID on shares to short and only after a 10 year moratorium to allow investors a return on investment for supporting the stock since they often incur heavy losses in pipeline development.
Seems plausible to me but unrealistic.
If so Partnerships should be forth coming.
"possibly holding the most valuable IP and pipelines in Immuno-Oncology (and other Immuno disciplines) around".
Capitalization & evaluation improving. Could initiate nice price movement. Expect more news before end of September. Stay tuned.
The science is evolving. There should be a ROI at some point.
Accumulated deficit to shareholders is $520,333,000. Perhaps
realized within next couple years with shift in focus and strategy.
That would be an interesting scenario. Perhaps something is in the works.
McShane No delisting for certain. The SP probably will not reach
the $ threshold due to massive shorting. Only exception would be some promising news with perhaps a subgroup out of failed SUNRISE but not very likely and/or announcement of another partnership arrangement.
Without upward price movement expect RS which will make PPHM Nasdaq complaint. The AVID news in the near term will not carry us to the promise land but will at-least improve valuations for the analyst.
My 2 cents
Couch Was being sarcastic, as along as they are in the money we have a chance with the science to be in the money.
BOD will never allow this to happen. Too much money to be had must keep this gravy train going. Perhaps a partner will come to the rescue only chance for shareholders. Yes I bought back in a little just in case something unpredictable happens and HUGE PR comes out and the stock launches through the stratosphere? It is about time?
"As we are discussing the possibility of moving off the Nasdaq to the OTC......soon becomes a whole lot more precarious".
Perhaps a raise in their package is in order because they will deliver? First things first though a RS to secure it.
"has the BOD offered cuts to their benefits package"?
Such as dropping out of Russell or we can use our imagination if you will. Optimism is always in the playbook.
The playbook must have some astronomical type of chain of events that are soon just beginning
Hornet Keep us in focus so none of us goes hog wild and buys up thousand of shares with out examining these PR'S more thoroughly.
Got deleted on last comment so I'll will agree on your comment.
Thanks to the short crowd I added more cheaper shares.
Vol picked up today will see what it delivers.
Vol picked up today will see what it delivers.
Perhaps some news will roll out to push up the SP to a buck. You never know. GL longs.
Per proxy
We do not have any present plan or intention to issue the additional shares of authorized but unissued common stock that would become available as a result of the proposed Reverse Split.
But no worries we have this planned down the road as it will probably become necessary. Not in proxy just my spin
Flew the coop this morning with my last 10K @.36.
RS keeps the boys in money but not the SH at least for now.
But maybe one day in the future something astronomical will happen?
Best wishes to all of the die hard longs you did your part.
Keep trolling on the outside looking in for now.
GLTA
added more shares good day. Marketing key from here.
added more shares good day. Marketing key from here.
Perhaps there research and investment provides an impetus of things to come.
Kennedy Capital Management
Disciplined Process
We work to identify companies that are able to reinvest in their business at attractive rates of return, and invest in those companies at prices we believe don’t adequately reflect the potential value creation from those investments.
A core tenet of Kennedy Capital’s investment philosophy is that the operating cash-flow returns of a business provide a crucial measure of corporate performance. We believe reinvesting cash-flow into high-return projects creates a powerful compounding effect, creating value for shareholders over time.
Active, Fundamental Bottom-Up Stock Picking
Led by our Director of Research, we use a detail-oriented, bottom-up proprietary research process driven by a team of a dozen sector-specific analysts. We believe this level of specialization provides a competitive advantage allowing us to regularly capitalize on overlooked opportunities.
Efficient Trading Capability
KCM has invested significant personnel and technological resources to seek the best possible trading executions. Trading is a key competency of the firm and we believe delivers trading cost savings for our clients.
Risk Management and Oversight
Our Investment Policy Committee has responsibility for risk management and adherence to investment guidelines. We avoid outsized sector over/under weights and rely on stock selection to generate performance.
Sell Discipline
We set clear objectives when taking a position and closely monitor progress against those targets. Primary drivers for our decision to sell a stock if a change occurs to alter Kennedy’s view of the likely progression of the business include:
Delivering results below our expectations
A management change
A change in competitive dynamics
When valuations become full
Simple swing trading in/out BIO stocks with an eye on holding shares if potential existed. Sunrise was potential-will see down the road what may develop POST failure.
Bought in 96 TCLN sold in 98. Bought in 2000 sold in 2005.
Bought in 2005 sold in 2012. Bought in 2014 sold in 2015.
Bought/sold in 2016 holding some shares for the big moment??
Flat line @.40 long enough. Time for some movement upward.
We need a catalyst.